This is an open-label Phase 1 study to determine the safety and tolerability of single-agent treatment with AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer that is refractory to standard therapies and a life expectancy of ≥6 months from the time tissue is obtained. A minimum of 6 (≤20) subjects will be enrolled to receive every other week subcutaneous injection of 240 μg AutoSynVax™ vaccine + 50 μg QS-21 Stimulon® adjuvant for up to 1 year.
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer